Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 6/20 | 0.34 |
| ▸ | CDK2 | P24941 | 4/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | CCNC | P24863 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17182866 | 0.80 | PDE4D (0.40) | PDE4DGSK3BCDK2CHEK1CCNA2 | |
| SCHEMBL15718407 | 0.80 | PDE4D (0.42) | PDE4DGSK3BCDK2PIM1PIM2 | |
| SCHEMBL17182839 | 0.78 | GSK3B (0.39) | PDE4DGSK3BCDK2MAPKAPK2 | |
| SCHEMBL17182832 | 0.75 | GSK3B (0.39) | PDE4DGSK3BCDK2PIM1PIM2 | |
| SCHEMBL17182815 | 0.75 | GSK3B (0.39) | PDE4DGSK3BCDK2PIM1PIM2 | |
| SCHEMBL17182817 | 0.75 | GSK3B (0.39) | PDE4DGSK3BCDK2PIM1PIM2 | |
| SCHEMBL17182921 | 0.75 | PDE4D (0.35) | PDE4DGSK3BCDK2CHEK1CCNA2 | |
| SCHEMBL15718900 | 0.74 | TTK (0.33) | PDE4DMALT1TTK | |
| SCHEMBL12583210 | 0.74 | CSNK2B (0.43) | — | |
| SCHEMBL17182871 | 0.74 | GPR119 (0.33) | PDE4DMALT1TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10106545-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-23 | — | — | US | disclosed |
| US-20170217966-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9573954-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-21 | — | — | US | disclosed |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | PDE4D 520/4885GSK3B 3725/4885CDK2 1483/4885 |
| US-10106545-B2 | Pyrazolopyrimidine compounds | CYP3A5, CYP3A7, DPYD | PDE4D 669/4885GSK3B 3890/4885CDK2 1430/4885 |
| US-20170217966-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | PDE4D 669/4885GSK3B 3890/4885CDK2 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.